
· Executive Brief
Polycystic Ovary Syndrome Month 2026
Move from recognition activity to a visible operating route with named owners and closed loops.

Leadership signal
Use Polycystic Ovary Syndrome Month to examine the system behind the message.
Leaders can use this window to test whether public information, service entry points, internal referrals, and follow-up responsibilities form one understandable route. The review should start with the experience of people using the system and the teams responsible for receiving them.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Polycystic ovary syndrome is a whole-person condition managed in pieces
Polycystic Ovary Syndrome Month draws attention to one of the most common endocrine conditions among women of reproductive age. Its effects reach well beyond fertility. People with the condition face metabolic, cardiovascular, liver and mental health risks, yet care is often split between gynecology, endocrinology, primary care and fertility services, with no single owner.
The evidence shows that this fragmentation is a system problem, not a clinical one. A multicenter evaluation of 1,321 first specialist consultations across eight secondary-care centers in five countries found substantial variation in models of care.[1] Documentation of emotional well-being screening ranged from 9.4% to 17.6%, and documentation of long-term cardiometabolic risk education from 0.7% to 29.9%.[1] The authors concluded that variation was driven by structural differences rather than clinical judgment.[1]
Patients describe the consequences. In a qualitative study of 24 participants at a university hospital obstetrics and gynecology clinic, symptom dismissal before diagnosis harmed well-being, and goals of care were perceived as focused narrowly on weight and fertility.[14] Participants turned to self-advocacy and social media as their main source of information.[14]
This evidence section adds to the executive guidance already on the page. It does not give individual clinical advice. It focuses on operating questions: how the model of care is organized, how mental health is screened, how cardiometabolic risk is found early and how patients are kept informed. It asks whether leaders can show, with their own data, that patients reach each recommended step.
The case for action is practical. Missed depression screening, late metabolic screening and repeated visits without a plan carry clinical and financial costs. A coordinated model can reduce those costs while improving the experience of patients who often feel unheard. It also gives boards a clear way to see whether women’s health commitments are reaching patients.
Current evidence
What the research says about mental health burden and metabolic risk
Depression is common and often undetected. In a case-control study of 164 women in Isfahan, Iran, depression prevalence was 80.5% among women with the condition compared with 53.7% among matched controls (odds ratio 3.56).[3] In a study of 47 women with phenotypes A and B, 24% had moderate to severe depression risk compared with 5% and 3% in control groups.[5] Body composition did not appear to explain the difference.[5] Women with the condition also reported lower quality of life in physical, environmental and overall domains.[5]
Prevalence remains high regardless of treatment choices. In a Thai comparative study of 96 women, depression prevalence was 37.50% among combined oral contraceptive users and 35.42% among non-users, with no significant association.[6] The authors recommended routine screening for early detection, regardless of the treatment approach.[6] In a separate cross-sectional study of 80 women, vitamin D deficiency was associated with greater depressive symptom severity, although causal relationships could not be established.[8]
Body image and social context shape the burden. A study of 221 women aged 18 to 30 in the United Arab Emirates, 94 of whom had the condition, found higher depressive symptoms and body image concerns among those affected.[11] The authors noted that cultural sensitivities around reproductive health have limited attention to these psychological effects.[11] A higher body mass index correlated with lower body satisfaction but was not significantly associated with depressive symptoms.[11]
Metabolic and liver risk begins in adolescence. In a U.S. national survey of 1,651 females aged 12 to 19, amenorrhea was associated with higher odds of elevated alanine aminotransferase (adjusted odds ratio 2.5).[2] Biochemical hyperandrogenism was also associated with elevated levels (adjusted odds ratio 2.6), and adolescents with amenorrhea had higher prevalence even with a normal body mass index.[2] The authors supported liver enzyme screening for youth with menstrual dysfunction, even without obesity.[2]
For executives, the evidence defines the scope of the pathway. Mental health and metabolic screening are not optional extras. They are core to the condition, and current documentation suggests they are often missed. The studies are small and come from many countries, so local data should confirm the pattern. Most health systems can begin by checking how often depression screening and metabolic testing appear in the records of patients with this diagnosis.
Figure 1
Depression is common among people with polycystic ovary syndrome, but estimates vary
Percent of women with the condition screening positive for depression or moderate to severe depression risk, as reported in each study. Values are copied from the cited studies [3], [4], [5], [6]; none is estimated.
Data note. These values come from different countries, tools and cutoffs, so this is an indirect comparison; the spread shows why a single agreed screening tool matters more than any one estimate.
Limitation. Small single-site samples; screening tools measure symptoms, not clinical diagnosis.
Figure data (4 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Depression, Beck Depression Inventory-II score of 20 or more | 80.5% | 82 women with the condition at one hospital in Isfahan, Iran, 2025 | [3] |
| Depression among combined oral contraceptive users, PHQ-9 | 37.5% | 48 users among 96 Thai women with the condition | [6] |
| Highest rate by screening tool and cutoff | 26.89% | 119 Thai women; rates ranged from 2.52% to 26.89% across tools | [4] |
| Moderate to severe depression risk | 24% | 47 women with phenotypes A and B compared with controls | [5] |

Continuum of care
Where the continuum breaks between symptoms, diagnosis and long-term care
The continuum of care for this condition begins with symptoms that are easy to dismiss. Irregular periods, acne, hair growth and weight change may be treated one at a time in different settings. Diagnosis can be delayed, and after diagnosis, long-term follow-up often has no clear owner. Patients may be told the condition matters only when they want to conceive, then lose contact with care until a later problem appears.
Patients describe the early part of the pathway as a struggle to be heard, sometimes across several clinicians. In the qualitative study, symptom dismissal before diagnosis contributed negatively to well-being and delayed care.[14] Participants found self-advocacy necessary to get answers.[14] The authors called for greater educational resources and a more comprehensive approach to management.[14]
The first specialist consultation is a pivotal handoff. In the multicenter models-of-care study, structural determinants including funding models, multidisciplinary team availability, administrative support and clinic organization drove variation in care processes.[1] Mapping to the Chronic Care Model showed limited decision support, weak care coordination and minimal reinforcement of self-management.[1] Centers with established multidisciplinary teams and structured follow-up pathways showed greater guideline alignment.[1] They also showed more complete biochemical assessment at the first consultation.[1]
Adolescence is a transition point that is easy to miss. The national adolescent survey found that menstrual dysfunction and hyperandrogenism were linked to elevated liver enzymes and suspected metabolic liver disease.[2] The authors called for earlier detection and more integrated endocrine and hepatic care.[2] Pediatric and adolescent clinics therefore need a defined route into metabolic screening and adult follow-up. Without it, young people diagnosed in adolescence may lose contact with care just as long-term risks begin to matter.
The common thread across these findings is that no single service owns the whole condition, from first symptoms through long-term risk. Leaders can define one accountable home for follow-up, set a standard first-visit bundle and track whether it is completed. They can also measure the interval from first symptom-related visit to documented diagnosis. That interval is a direct measure of whether early symptoms are being recognized. Reviewing a sample of delayed cases can show where symptoms were seen but not connected.
Figure 3
Why the pathway breaks
People
- Clinicians who dismiss early symptoms
- Too few dietitians and behavioral health staff attached to clinics
- Only moderate knowledge among future health professionals
Process
- No standard first-visit bundle
- Emotional well-being screening rarely documented
- No single owner for long-term follow-up
Technology
- Limited decision support in the record
- Screening tools and cutoffs not standardized
- Patients relying on social media for information
Environment
- Cultural sensitivity around reproductive health
- Weight stigma in clinical encounters
- Separate locations for each service
Policy
- Funding models that do not support multidisciplinary teams
- Limited administrative support
- Screening criteria tied to body size
Measurement
- Time to diagnosis not tracked
- Guideline adherence not audited
- Results not stratified by age, income or language
Unranked qualitative cause-and-effect diagram for the outcome in the box: People with polycystic ovary syndrome experience delayed diagnosis and miss recommended mental health and cardiometabolic care Causes are assembled from the cited literature [1], [2], [3], [4], [11], [13], [14]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Clinicians who dismiss early symptoms; Too few dietitians and behavioral health staff attached to clinics; Only moderate knowledge among future health professionals |
| Process | No standard first-visit bundle; Emotional well-being screening rarely documented; No single owner for long-term follow-up |
| Technology | Limited decision support in the record; Screening tools and cutoffs not standardized; Patients relying on social media for information |
| Environment | Cultural sensitivity around reproductive health; Weight stigma in clinical encounters; Separate locations for each service |
| Policy | Funding models that do not support multidisciplinary teams; Limited administrative support; Screening criteria tied to body size |
| Measurement | Time to diagnosis not tracked; Guideline adherence not audited; Results not stratified by age, income or language |
Access
Making nutrition, exercise and psychological support reachable
Non-drug interventions for mental health show strong pooled effects. A meta-analysis of 29 studies with 2,055 participants found that non-pharmaceutical interventions significantly lowered depression (standardized mean difference -2.57) and anxiety (-2.36).[12] Emotional quality of life also improved.[12] These interventions depend on access to services such as counseling, exercise and nutrition support. Pooled effects of this size should be read cautiously, because the studies varied widely in design and content.
Exercise programs are one route that many systems can offer through existing rehabilitation or wellness services. A meta-analysis of seven randomized trials found that exercise interventions reduced depressive symptoms compared with controls (standardized mean difference -0.75).[9] The authors urged caution because of the small number of trials and limited sample sizes.[9] Health systems can still treat structured exercise as a referral option and measure uptake. In exploratory analyses, resistance exercise and programs with higher weekly frequency or longer duration showed numerically larger effects.[9]
Nutrition support is another. In a randomized trial of 52 women aged 18 to 45, eight weeks of a low-calorie MIND diet reduced depression and anxiety scores compared with a control group.[15] A systematic review of five randomized trials found that probiotic supplementation was associated with improvements in sleep quality and depressive symptoms, although evidence remained limited.[10] Dietitians are therefore part of the mental health pathway as well as the metabolic one.
Treatment of the condition itself may also support mood, which strengthens the case for coordinated care. In a naturalistic study of 33 women receiving 12 weeks of treatment, mainly spironolactone and oral contraceptives, depression and anxiety symptoms improved.[7] The study was preliminary and lacked randomization, but it suggests that endocrine and mental health care should be coordinated rather than separated.
Leaders can design access around these options, starting with the services they already run. Many systems have dietitians, exercise programs and behavioral health clinicians who are simply not linked to this patient group. A single referral that opens nutrition, exercise and behavioral health support, delivered in person or by telehealth, reduces the number of steps patients must take. Each option needs a completion measure, not only a referral count. Telehealth can help patients who live far from specialty clinics or who find repeated in-person visits hard to fit around work and family. Group education sessions can also extend dietitian and behavioral health capacity while giving patients a chance to learn from peers.
Executive guidance · System route
Connect the month to an accountable system route.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Navigate specialty boundaries
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Navigate specialty boundaries
Clarify how questions reach the appropriate locally designated resource when knowledge, capacity, or responsibility spans multiple teams or organizations.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Navigate specialty boundaries | Clarify how questions reach the appropriate locally designated resource when knowledge, capacity, or responsibility spans multiple teams or organizations. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Equity gaps in recognition, screening and support
Social and economic factors shape the burden of the condition, not only its clinical features. In the Isfahan study, lower education and lower financial status were associated with greater depressive symptoms, and lower education remained independently associated with depression.[3] The authors recommended culturally sensitive interventions, particularly for women with socioeconomic vulnerabilities.[3]
Cultural context can hide need, even when services exist. In the United Arab Emirates study, the authors noted that cultural sensitivities around reproductive health have left the psychological effects of the condition underexplored.[11] Health systems serving diverse communities may see similar barriers. Patients may be reluctant to discuss menstrual or body image concerns, especially with clinicians who do not share their language or background.
Adolescents are another group at risk of missed screening, partly because their symptoms are often attributed to normal development. In the national adolescent survey, amenorrhea was reported by 2.8% of participants, and those affected had higher liver enzyme prevalence even with a normal body mass index.[2] Screening protocols that rely on body size alone may therefore miss young people at risk.[2] Adolescents may also be less likely to raise menstrual concerns, so clinics serving them need a direct question in routine visits.
Awareness also varies. A survey of 243 female health sciences students in Saudi Arabia found that 58.5% had moderate knowledge of the condition and 52.4% had a positive attitude toward it.[13] Knowledge and attitude were strongly associated, and the authors recommended targeted health education to promote proactive management.[13] If future health professionals have only moderate knowledge, the general public may know even less. Low awareness can delay the first visit as well as the diagnosis.
For an executive team, equity means stratified measurement and a plan to act on what it shows. Time to diagnosis, completion of mental health and metabolic screening, and access to nutrition and behavioral health can be reported by age, race, ethnicity, language, insurance and neighborhood. Gaps can then guide outreach and interpreter-supported education. Patient advisory groups that include adolescents, women from different cultural backgrounds and those with lower incomes can help review materials and pathways. Their input can reveal barriers, such as cost of dietitian visits or discomfort discussing symptoms, that do not appear in clinical data.

Human infrastructure
Building the multidisciplinary team the condition requires
This condition needs a team that most clinics do not have in one place. Gynecologists, endocrinologists, primary care clinicians, dietitians, exercise professionals, psychologists and nurses each address part of the burden. When those roles are spread across separate departments, patients carry the coordination work. They repeat their history, wait for separate appointments and sometimes receive conflicting advice.
Team structure makes a measurable difference to what patients receive at their first visit. In the multicenter models-of-care study, multidisciplinary team availability and administrative support were among the structural drivers of variation.[1] Centers with established multidisciplinary teams and structured follow-up showed more complete biochemical assessment.[1] The authors concluded that strengthening multidisciplinary capacity is essential to improve guideline adherence.[1]
Clinicians need agreed screening tools, because the choice of tool changes who is identified and who is referred for support. In a Thai study of 119 women, depression rates varied from 2.52% to 26.89% depending on the screening tool and cutoff used.[4] Agreement between some tools was poor, while specific cutoffs yielded strong agreement.[4] The authors proposed the PHQ-9 with a score of 10 or more as the most suitable instrument in their population and noted the brevity of the PHQ-2.[4]
Education for the current and future workforce matters too. The student survey found only moderate knowledge among most future health professionals and recommended targeted health education programs.[13] In the qualitative study, patients described goals of care that felt misaligned with their own, often focused only on weight and fertility.[14] Training can address both knowledge gaps and the way clinicians frame care. Short, practical modules for primary care and emergency clinicians can help them recognize the condition and route patients correctly.
For leaders, the workforce question is one of design and funding rather than individual effort. A defined team with dietitian, behavioral health and nursing time attached to the clinic, a shared screening protocol and administrative support for scheduling and follow-up can turn guideline recommendations into routine practice. Leaders can review dietitian and behavioral health wait times for these patients and compare them with wait times for other chronic conditions. Where capacity is short, shared group visits and telehealth sessions can extend the team.
Executive guidance · Operating dashboard
Review reliability, not campaign activity alone.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Specialty-route clarity
Can frontline and access teams identify the appropriate receiving resource without relying on personal memory?
- Candidate local measure
- Locally defined misroutes, searches, returned work, unresolved referrals, escalation, and navigation feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Specialty-route clarity | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Transfer responsibility with acknowledgment and visibility.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Identify the designated receiving resource and keep the request visible when the appropriate owner is not immediately available.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Connect operating signals to accountable executive review.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Specialty-route clarity | Can frontline and access teams identify the appropriate receiving resource without relying on personal memory? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable polycystic ovary syndrome pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Single accountable home for long-term follow-up | Patients cycle between services with no plan owner | Women’s health service line leader | Share of diagnosed patients with a named follow-up clinic |
| Standard first-visit bundle aligned with guidelines | Investigations, education and screening missed | Gynecology and endocrinology clinic directors | Bundle completion rate at first specialist visit |
| Agreed depression screening tool and cutoff | Inconsistent detection and missed referrals | Behavioral health integration lead | Screening completion and referral completion for positive screens |
| Metabolic and liver screening including adolescents | Cardiometabolic and liver risk found late | Primary care and adolescent medicine leads | Share of patients with documented metabolic screening, including those with normal body mass index |
| Single referral to nutrition, exercise and behavioral support | Patients drop out between separate referrals | Ambulatory access director | Completion of at least one support service within a set period |
| Documented cardiometabolic risk education | Patients unaware of long-term risks | Nursing education lead | Share of first visits with documented education |
Control points derived from the cited evidence [1], [2], [4], [9], [12], [14] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating with patients in ways that build trust
Trust begins with being heard, especially for patients who have felt dismissed before. In the qualitative study, participants described symptom dismissal and goals of care that focused on weight management and fertility.[14] Many relied on social media as their main source of information.[14] Health systems have an opportunity to provide trustworthy, accessible information that patients can find before they search elsewhere. Plain-language materials, reviewed by patients and clinicians, can explain the range of symptoms and the services available.
Education at the first visit is often missing. In the multicenter study, documentation of long-term cardiometabolic risk education ranged from 0.7% to 29.9% across centers.[1] The Chronic Care Model mapping showed minimal reinforcement of patient self-management.[1] Structured patient education, documented in the record, is a communication standard that clinics can audit. Written summaries after the first visit can help patients remember what was discussed and what happens next, including which team to contact with questions.
Mental health conversations need a routine, protected place in every care visit. Studies across several countries recommend routine psychological screening for people with this condition.[3][6] When screening is routine, it signals that mental health is part of the condition rather than a separate concern. It also reduces stigma for patients who might not raise it themselves. Clinicians can explain why they are asking, so the question feels like care rather than judgment.
Messages should avoid weight stigma, which can drive patients away from care. The study of 47 women found that body composition did not appear to determine depression risk or poorer quality of life.[5] Communication that focuses only on weight may therefore miss what matters to patients and may discourage them from returning. Asking patients which symptoms matter most to them at each visit is a simple, measurable practice that keeps care aligned with their goals.
Public messages during the observance can reinforce these standards. They can describe the range of symptoms, explain how to reach evaluation and support, and invite patients to share their priorities. They should be tested with patients from different age, language and cultural groups and should avoid promising outcomes the organization cannot yet measure. Social media channels, where many patients already look for answers, can carry the same approved messages.[14]

Executive guidance · 90-day plan
Use 90 days to correct one visible operating barrier.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Polycystic Ovary Syndrome Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Document and test one specialty-navigation route so it does not depend on informal knowledge alone.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Polycystic Ovary Syndrome Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Document and test one specialty-navigation route so it does not depend on informal knowledge alone. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Pair recognition with a system people can trust.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Connect the message to one usable, measured, and sustained operating change.
Executive action kit · Month observance
Turn Polycystic Ovary Syndrome Month into accountable action.
Move from recognition activity to a visible operating route with named owners and closed loops.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, specialty navigation, coordination, and continuing support pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review distance, coverage, language, disability, digital access, and the burden placed on people and families to coordinate complex routes themselves.
Five-minute briefing
Inspect the operating sequence
Listen with people and families using the pathway, primary care, specialty services, navigation teams, and support organizations. Find one unclear referral ownership, fragmented information, or a connection that is not completed, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Navigate specialty boundaries
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined misroutes, searches, returned work, unresolved referrals, escalation, and navigation feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During Polycystic Ovary Syndrome Month, our organization will connect awareness with a practical review of the information, specialty navigation, coordination, and continuing support pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Polycystic Ovary Syndrome Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Arshad A, Armeni E, Yee ALJ, Ali A, Manta A, Pandey S, et al. Models of care on the management of women with polycystic ovary syndrome: A multicentre study. Endocrine. 2026;91(1). https://doi.org/10.1007/s12020-026-04623-6
- 2.Noon SL, Chun LF, Mackay G, Schwimmer JB. Menstrual Dysfunction Is Associated With Elevated Liver Enzymes in Adolescent Females: A United States Population-Based Study. Journal of Adolescent Health. 2026;78(4):633-638. https://doi.org/10.1016/j.jadohealth.2025.12.254
- 3.Ghobadi S, Lonbani MB, Abedini Pozve K. Comparison of depression frequency in women with polycystic ovary syndrome and healthy controls: A case-control study in Isfahan, Iran (2025). Journal of Affective Disorders Reports. 2026;24. https://doi.org/10.1016/j.jadr.2026.101049
- 4.Tantanavipas S, Saipanish R, Sophonsritsuk A, Niransuk P. Comparison of HADS-D, PHQ-9 and PHQ-2 for detecting depression in women with polycystic ovary syndrome. Journal of Psychosomatic Obstetrics and Gynaecology. 2026;47(1):2660700. https://doi.org/10.1080/0167482x.2026.2660700
- 5.Ponce T, Vigário PDS, Almeida CDP, Conceição FL. Assessment of body composition, quality of life, and depression in women with polycystic ovary syndrome. Archives of Endocrinology and Metabolism. 2026;70(3). https://doi.org/10.20945/2359-4292-2026-0036
- 6.Prommani P, Sophonsritsuk A, Saipanish R, Anantaburana M, Tantanavipas S. Association between combined oral contraceptive pills and depression in women with polyendocrine metabolic ovarian syndrome (formerly polycystic ovary syndrome): a comparative cross-sectional study. BMC Women’s Health. 2026;26(1). https://doi.org/10.1186/s12905-026-04641-6
- 7.Douglas KM, Sukhapure M, Porter RJ, Fenton A, Eggleston K. Changes in facial emotion processing and depression and anxiety symptoms with polycystic ovary syndrome treatment: a longitudinal, naturalistic study. Archives of Women’s Mental Health. 2026;29(3). https://doi.org/10.1007/s00737-026-01725-y
- 8.Postaci ES, Cakina S, Beyazit F. Relationship between vitamin D levels and depression in women with polycystic ovary syndrome. Vojnosanitetski Pregled. 2026;83(7):443-450. https://doi.org/10.2298/vsp250925035s
- 9.Zheng Y, Zhang DQ. Exercise-based interventions for depression in women with polycystic ovary syndrome: a systematic review and meta-analysis. Frontiers in Public Health. 2026;14:1802184. https://doi.org/10.3389/fpubh.2026.1802184
- 10.Łagowska K, Ptaszyńska D. Effects of Probiotic Supplementation on Mental Health and the Risk of Depression in Women with Polycystic Ovary Syndrome: A Systematic Review of Randomized Controlled Trials. Nutrients. 2026;18(2):307. https://doi.org/10.3390/nu18020307
- 11.AlMekhlafi SA, Campo-Redondo MS. Association between body image satisfaction and depressive symptoms among young women in the UAE with Polycystic Ovary Syndrome (PCOS) and Non-PCOS: A comparative quantitative cross-sectional study. PLOS ONE. 2026;21(1):e0333908. https://doi.org/10.1371/journal.pone.0333908
- 12.Yin MXC, Huang MY, Zhao YF, Chen XY. Non-pharmaceutical interventions targeting psychological health in women with polycystic ovary syndrome:a systematic review and meta-analysis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2026;106:102719. https://doi.org/10.1016/j.bpobgyn.2026.102719
- 13.Abdelrahman WM, Abouelfettoh AM, Nabil Aboushady RM, Alomar MO, Mobaraki MM, Almejna WA, et al. Reframing Reproductive Health: Awareness of Female Students at King Saud bin Abdulaziz University for Health Sciences Toward Polycystic Ovary Syndrome. Nursing Forum. 2026;2026:1-9. https://doi.org/10.1155/nuf/8851904
- 14.Zhang AZ, Sehrt M, Ley SA, Ross KV, Phimphasone-Brady P, McKenney KM. Gaps and opportunities in polycystic ovary syndrome care—a qualitative study. F&S Reports. 2025. https://doi.org/10.1016/j.xfre.2025.05.011
- 15.Kabiri SS, Javanbakht Z, Zangeneh M, Moludi J, Saber A, Salimi Y, et al. The effects of MIND diet on depression, anxiety, quality of life and metabolic and hormonal status in obese or overweight women with polycystic ovary syndrome: a randomised clinical trial. British Journal of Nutrition. 2024:1-14. https://doi.org/10.1017/s0007114524001168
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Variation in models of care and guideline-recommended documentation | [1] | 2026 | Current evidence | Eight secondary-care centers in five countries; retrospective documentation may undercount care delivered. |
| Depression prevalence and risk compared with controls | [3] [5] | 2026 | Current evidence | Single-site case-control and cross-sectional studies at single sites; small samples. |
| Depression and oral contraceptive use | [6] | 2026 | Current evidence | Cross-sectional Thai study of 96 women; limited statistical power. |
| Vitamin D deficiency and depressive symptoms | [8] | 2026 | Current evidence | Cross-sectional study of 80 women; causation not established. |
| Body image and depressive symptoms in young women | [11] | 2026 | Equity and trust | Single-country cross-sectional survey. |
| Menstrual dysfunction, hyperandrogenism and liver enzymes in adolescents | [2] | 2026 | Current evidence | National survey data; self-reported amenorrhea; cross-sectional associations. |
| Patient experience of dismissal and misaligned goals | [14] | 2025 | Continuum of care | Qualitative study of 24 participants at one university clinic. |
| Non-pharmaceutical and exercise interventions for mental health | [12] [9] | 2026 | Access | Heterogeneous interventions; small trials; large pooled effects may overstate benefit. |
| Diet and probiotic interventions | [15] [10] | 2026, 2024 | Access | One small eight-week trial and a review of five small trials. |
| Mood changes during endocrine treatment | [7] | 2026 | Access | Naturalistic, nonrandomized study of 33 women. |
| Agreement among depression screening tools | [4] | 2026 | Human infrastructure | Thai sample of 119 women; cutoffs may differ in other populations. |
| Awareness among future health professionals | [13] | 2026 | Equity and trust | Purposive sample at one Saudi university. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

